

Q (c) optionally, separating the PEGylated protein or analog thereof from non-PEGylated protein or analog thereof.

48. A method of claim 47 wherein said polyethylene glycol molecule has a molecular weight of about 2 kDa to about 100 kDa.

49. The PEGylated protein or analog thereof produced by the process of claim 47.

---

#### Remarks

The Applicants request entry of the foregoing amendments in the above-identified application. In these amendments, claims 39-49 as amended find support throughout the application (see especially p. 21, lines 12-23), and are intended solely to more clearly define the scope with which the invention is claimed.

The present application is a continuation of U.S. Patent No. 5,824,784. Submitted herewith is a Terminal Disclaimer with respect to that patent, which should moot any potential for a rejection under the judicially created doctrine of obviousness-type double patenting.

All pending claims 39-49 are thus believed to be allowable and an early notice thereof is respectfully solicited.

The Applicants do not intend by these or any other amendments to abandon the subject matter of any claim as originally presented, and reserve the right to pursue such subject matter in other applications, such as continuing applications and divisional applications.

Enclosed is a check in the amount of \$110.00, the requisite fee for filing the Terminal Disclaimer. Applicants authorize the Patent Office to charge or credit any underpayment or

overpayment to Deposit Account No. 13-2855. A copy of this paper is included for this purpose.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402

Date: October 24, 2001



---

Mark H. Hopkins  
Reg. No. 44,775